Trim 20-25% into bounce zone; hold residual as structural defense limits full-exit case
Measured 20-25% trim captures technical risk premium without abandoning structural thesis or violating binding prior lessons (9/21 preemptive trim lesson caps magnitude; 10/01 ATR anchoring mandates $390 stop not MA-based). Rejects full Sell (forfeits 0.43-beta defensive ballast, 2.48% dividend carry, re-engagement optionality at $409), Aggressive 25-40% trim (violates 9/21 lesson), and Conservative Hold (ignores lower-highs deterioration and $24.45 forward EPS vulnerability). Rejects $414.50 MA-based stop and $397 hard stop as too tight per prior lesson reflections.
| Position | Action |
|---|---|
| At bounce zone ($402-405) | Trim 20-25% of current AMGN exposure |
| Close below $390 (1.3 ATR below entry per 10/01 ATR anchoring lesson) | Hard stop - exit remaining position |
| Close above 50 SMA at $409 on volume ≥ 4M | Flip to neutral - repurchase trimmed shares |
| Confirmed close below $397.50 (Bollinger middle) on volume ≥ 4M | Add to trim with next target at $365.75 (Bollinger lower band) |
| Into Q3 earnings (3 weeks) | Hold remaining position; reassess post-print |
Amgen is an underappreciated large-cap compounder trading at a technical pullback within a confirmed uptrend, with accelerating fundamentals, a deleveraging balance sheet, and binary catalysts that the market is not pricing.
| Indicator | Value | Signal |
|---|---|---|
| 10 EMA | 407.54 | bearish |
| 50 SMA | 409.12 | neutral |
| 200 SMA | 361.40 | bullish |
| RSI (14) | 47.80 | neutral |
| MACD | +0.71 | neutral |
| MACD Signal | -0.13 | neutral |
| MACD Histogram | +0.84 | bearish |
| Bollinger Upper Band | 429.24 | neutral |
| Bollinger Middle Band (20 SMA) | 397.50 | neutral |
| Bollinger Lower Band | 365.75 | neutral |
| ATR (14) |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Close below $397.50 on volume ≥ 4M
Then: Add to trim targeting $365.75
Q2 2026 was a record quarter with accelerating momentum across all metrics
↩ rebuts: “Bear anchored to legacy concerns rather than current fundamental trajectory”
EV: +6.5% to Target 1 ($429), +11% to Target 2 ($447) · concedes: Q3 earnings is a binary event; if Repatha volumes disappoint, biosimilar erosion accelerates, or MariTide guidance wobbles, the stock sells off hard; MariTide Phase 3 data is a true binary—failure means obesity optionality goes to zero and multiple compresses; IRA/PBM reform could resurface as a 2026 election issue in Q4; Short-term momentum is weak (price below 10 EMA and 50 SMA); If $397.50 breaks on volume, next stop is Bollinger lower band at $365.75 and possibly 200 SMA at $361.40
AMGN is a fully-priced, debt-laden mega-cap with a binary Q3 catalyst and deteriorating technicals — the asymmetric risk-reward favors the short side into earnings, not the long side.
EV: -$37.23 to -$41.58 (9.2% to 10.3% downside to $365.75-$361.40) · concedes: Q3 earnings could surprise to the upside — if Repatha volume accelerates, biosimilar erosion stays contained, and MariTide guidance is constructive, stock could retest $429-$447; would close short in that case; Deleveraging is real — $4.9B annual net debt reduction is meaningful and equity value accrual is non-trivial if sustained; Long-term uptrend intact — if price holds $397.50 and reclaims $409, the coiled spring thesis has merit; would flip to neutral; Defensive characteristics (0.41 beta, 2.5% yield) provide some downside cushion in market shock scenarios; Horizon integration largely complete — rare disease franchise (Tepezza, Krystexxa) is a real growth driver if managed well; Every bull case requires confirmation to be tradeable — not saying AMGN is going to zero, but better risk-reward on short side than long side into Q3
→ vs conservative: Backward-looking earnings focus (record Q2, $5B net debt reduction, dividend coverage) ignores that current price already pays premium for 52% forward EPS growth that may not materialize given biosimilar erosion on Enbrel and obesity pipeline entering duopoly with Lilly/Novo
→ vs neutral: Waiting for Bollinger squeeze confirmation above $490 or breakdown below $397 is too late; the September 8 gap down from $437 to $393 already changed market structure, and declining volume on the bounce confirms distribution rather than accumulation
| 10.07 |
| neutral |
| VWMA (20) | 401.06 | neutral |
Support: 397.5 · 382.84 · 365.75 · 361.4 | Resistance: 429.24 · 409.12
AMGN is in a short-term pullback within a still-intact medium-term uptrend. Short-term momentum is bearish (price below 10 EMA and 50 SMA), but the long-term trend remains bullish with price 11.5% above the 200 SMA. Volatility is compressing (ATR declining, Bollinger bands narrowing), suggesting an imminent directional move. Key levels to watch: resistance at $409.12 (50 SMA) and support at $397.50 (Bollinger middle band). The ATR-based stop reference is $392.91.
Market Cap
$217.86 B
Share Price (52-wk High)
$447.03
Share Price (52-wk Low)
$288.00
50-Day Moving Average
$409.48
200-Day Moving Average
$364.54
Beta
0.407
P/E (TTM)
25.03x
Forward P/E
16.48x
PEG Ratio
2.43
Price-to-Book
18.64x
EPS (TTM)
$16.10
Forward EPS
$24.45
Dividend Yield
2.50%
Revenue (TTM)
$38.09 B
Gross Profit (TTM)
$27.39 B
EBITDA (TTM)
$17.27 B
Net Income (TTM)
$8.74 B
Operating Margin (TTM)
35.5%
Profit Margin (TTM)
23.0%
Free Cash Flow (TTM)
$8.65 B
Annual Dividends
$5.1 B
Total Assets (Q2 2026)
$95.64 B
Total Liabilities (Q2 2026)
$83.95 B
Stockholders' Equity (Q2 2026)
$11.69 B
Long-Term Debt (Q2 2026)
$51.86 B
Current Debt (Q2 2026)
$5.45 B
Total Debt (Q2 2026)
$57.30 B
Cash & Equivalents (Q2 2026)
$13.99 B
Net Debt (Q2 2026)
$43.32 B
Goodwill & Intangibles (Q2 2026)
$39.16 B
Working Capital (Q2 2026)
$9.46 B
Current Ratio (Q2 2026)
1.37
Net Debt / EBITDA
~2.5x
ROE (TTM)
91.5%
ROA (TTM)
8.7%
Q2 2026 Revenue
$10.05 B
Q2 2026 Operating Income
$3.51 B
Q2 2026 Net Income
$2.38 B
Q2 2026 Diluted EPS
$4.37
Q2 2026 FCF
$3.49 B
Q2 2026 Sequential Revenue Growth
+16.6%
Q2 2026 Y/Y Net Income Growth
+65.9%
2025 Revenue
$36.75 B
2025 Net Income
$7.71 B
2025 Diluted EPS
$14.23
2025 FCF
$8.10 B
2024 Revenue
$33.42 B
2024 Net Income
$4.09 B
2024 Diluted EPS
$7.56
2024 FCF
$10.39 B
2023 Revenue
$28.19 B
2023 Net Income
$6.72 B
2022 Revenue
$26.32 B
2022 Net Income
$6.55 B
R&D Spending 2025
$7.27 B
R&D Spending 2022
$4.43 B
Shares Outstanding (TTM)
~541 M
Interest Expense Q2 2026 Run-rate
~$670 M/quarter
Strengths
Concerns
Amgen Inc. delivered a breakout Q2 2026 with record revenue of $10.05B and EPS of $4.37, while actively deleveraging with net debt declining $5B year-over-year to $43.32B. The TTM income statement shows revenue of $38.09B with strong profitability metrics including 35.5% operating margin, 23% net margin, and $8.65B in free cash flow. The balance sheet is improving with cash nearly doubling to $13.99B and working capital expanding to $9.46B, though $57.3B in total debt remains elevated with a manageable 2.5x Net Debt/EBITDA ratio. Key risks include GLP-1 competition for MariTide, patent cliffs on legacy drugs, and high valuation multiples, while bullish catalysts center on the MariTide obesity pipeline, accelerating quarterly momentum, and defensive characteristics including low beta and attractive dividend yield.